Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CDK8-IN-13 is a CDK8 inhibitor (IC50: 51.9 nM) with potent, selective and oral activity. CDK8-IN-13 induces apoptosis and reduces the expression of p-STAT1 S727 and p-STAT5 S726. CDK8-IN-13 exhibits anti-tumour activity.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 38.00 | |
5 mg | In stock | $ 95.00 | |
10 mg | In stock | $ 139.00 | |
25 mg | In stock | $ 233.00 | |
50 mg | In stock | $ 349.00 | |
100 mg | In stock | $ 516.00 | |
500 mg | In stock | $ 1,090.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 88.00 |
Description | CDK8-IN-13 is a CDK8 inhibitor (IC50: 51.9 nM) with potent, selective and oral activity. CDK8-IN-13 induces apoptosis and reduces the expression of p-STAT1 S727 and p-STAT5 S726. CDK8-IN-13 exhibits anti-tumour activity. |
Targets&IC50 | CDK8:51.9 nM |
In vitro |
CDK8-IN-13 (compound 43 ; 1, 2.5, 5, 10 µM ; 12 h) decreased p-STAT1 S727 and p-STAT5 S726 expression in HCT-116 cells in a dose-dependent manner.[1] CDK8-IN-13 (0, 1, 5, 10 µM ; 48 h) induced apoptosis in a dose-dependent manner.[1] |
In vivo | CDK8-IN-13 (40, 80 mg/kg ; orally ; for 15 days) inhibits tumor growth in a dose-dependent manner in mice.[1] |
Molecular Weight | 237.26 |
Formula | C14H11N3O |
CAS No. | 918523-75-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 112.5 mg/mL (474.2 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CDK8-IN-13 918523-75-8 Apoptosis Cell Cycle/Checkpoint CDK CDK8IN13 inhibitor inhibit